白蛋白纳米颗粒的制备研究进展
|
摘要
由于可以增强药物的靶向性、降低游离药物的毒副作用,基于纳米颗粒的药物递送系统在医学领域具有广泛应用。白蛋白是血浆中含量最多的蛋白质,具有生物相容性好、无免疫原性、可生物降解等特性,是制备纳米颗粒的理想材料。现有白蛋白纳米颗粒的制备方法主要有去溶剂化法、自组装法、乳化法、双乳化法、热凝胶、喷雾干燥、nab~(TM)技术、pH凝聚法等。由于制备原理及制备条件的差异,各方法表现出的优缺点也不尽相同。综述近年来白蛋白纳米颗粒的制备研究进展,按照制备方法分类进行介绍,并对当前白蛋白纳米颗粒研究领域所面临的困境及未来的发展方向进行探讨。
In the past decades, drug delivery systems based on nanoparticles have been increasingly applied in medical fields, aiming to improve the target activity of drugs and reduce the untoward effects. Among various polymers, albumin is an ideal material for the formulation of nanoparticle-based drug delivery systems. As the most abundant protein in plasma, albumin has many advantages, such as good biocompatibility, biodegradability and lack of immunogenicity. There is a list of approaches to prepare albumin nanoparticles, including desolvation, self-assembly, emulsification, double emulsification, thermal gelation, spray drying, nab-technology and pH-coacervation. Due to the differences in the mechanism and conditions of preparation, each method has its own advantages and disadvantages. This article provided an overview of research progresses in different albumin-based formulations according to preparation methods. The current difficulties confronted by albumin nanoparticles and the future development directions were also discussed.
In the past decades, drug delivery systems based on nanoparticles have been increasingly applied in medical fields, aiming to improve the target activity of drugs and reduce the untoward effects. Among various polymers, albumin is an ideal material for the formulation of nanoparticle-based drug delivery systems. As the most abundant protein in plasma, albumin has many advantages, such as good biocompatibility, biodegradability and lack of immunogenicity. There is a list of approaches to prepare albumin nanoparticles, including desolvation, self-assembly, emulsification, double emulsification, thermal gelation, spray drying, nab-technology and pH-coacervation. Due to the differences in the mechanism and conditions of preparation, each method has its own advantages and disadvantages. This article provided an overview of research progresses in different albumin-based formulations according to preparation methods. The current difficulties confronted by albumin nanoparticles and the future development directions were also discussed.
引文
[1] Wilson B, Paladugu L, Priyadarshini SR, et al. Development of albumin-based nanoparticles for the delivery of abacavir [J]. Int J Biol Macromol, 2015, 81: 763-767.
[2] Sun Tianmeng, Zhang YS, Pang Bo, et al. Engineered nanoparticles for drug delivery in cancer therapy [J]. Angew Chem Int Edit, 2014, 53(46): 12320-12364.
[3] Kinoshita R, Ishima Y, Chuang VTG, et al. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer [J]. Biomaterials, 2017, 140: 162-169.
[4] Loureiro A, Azoia NG, Gomes AC, et al. Albumin-based nanodevices as drug carriers [J]. Curr Pharm Design, 2016, 22(10): 1371-1390.
[5] Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles [J]. J Control Release, 2008, 132(3): 171-183.
[6] Hawkins MJ, Soon-shiong P, Desai N. Protein nanoparticles as drug carriers in cli-nical medicine [J]. Adv Drug Deliv Rev, 2008, 60(8): 876-885.
[7] Lin Tingting, Zhao Pengfei, Jiang Yifan, et al. Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy [J]. ACS Nano, 2016, 10(11): 9999-10012.
[8] Chen Qian, Liu Zhuang. Albumin carriers for cancer theranostics: A conventional platform with new promise [J]. Adv Mater, 2016, 28(47):10557-10566.
[9] Kudarha RR, Sawant KK. Albumin based versatile multifunctional nanocarriers for cancer therapy: Fabrication, surface modification, multimodal therapeutics and imaging approaches [J]. Mater Sci Eng C, 2017, 81:607-626.
[10] Sheng Zonghai, Hu Dehong, Zheng Mingbin, et al. Smart human serum albumin-indocyanine green nanoparticles generated by programmed assembly for dual-modal imaging-guided cancer synergistic phototherapy [J]. ACS Nano, 2014, 8(12): 12310-12322.
[11] Wong LR, Ho PC. Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: Implications for the treatment of Alzheimer′s disease [J]. J Pharm Pharmacol, 2018, 70(1): 59-69.
[12] Jeong JH, Nguyen HK, Lee JE, et al. Therapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage [J]. Int J Nanomed, 2016, 11: 3101-3109.
[13] Langiu M, Dadparvar M, Kreuter J, et al. Human serum albumin-based nanoparticle-mediated in vitro gene delivery [J]. PLoS ONE, 2014, 9(9).
[14] Adiseshaiah PP, Crist RM, Hook SS, et al. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer [J]. Nat Rev Clin Oncol, 2016, 13(12): 750-765.
[15] Sundar S, Kundu J, Kundu SC. Biopolymeric nanoparticles [J]. Sci Technol Adv Mater, 2010, 11(1): 014104.
16] Kratz F. A clinical update of using albumin as a drug vehicle — A commentary [J]. J Control Release, 2014, 190(190): 331-336.
[17] Carter DC, He X, Munson SH, et al. Three-dimensional structure of human serum albumin [J]. Science, 1989, 244(4909): 1195-1198.
[18] Zsila F. Subdomain IB is the third major drug binding region of human serum albumin: toward the three-sites model [J]. Mol Pharmaceut, 2013, 10(5): 1668-1682.
[19] Jahanban-Esfahlan A, Dastmalchi S, Davaran S. A simple improved desolvation method for the rapid preparation of albumin nanoparticles [J]. Int J Biol Macromol, 2016, 91: 703-709.
[20] Bunschoten A, Buckle T, Kuil J, et al. Targeted non-covalent self-assembled nanoparticles based on human serum albumin [J]. Biomaterials, 2012, 33(3): 867-875.
[21] Majorek KA, Porebski PJ, Dayal A, et al. Structural and immunologic characterization of bovine, horse, and rabbit serum albumins [J]. Mol Immunol, 2012, 52: 174-182.
[22] Furst W, Banerjee A. Release of glutaraldehyde from an albumin-glutaraldehyde tissue adhesive causes significant in vitro and in vivo toxicity [J]. Ann Thorac Surg, 2005, 79(5): 1522-1529.
[23] Wacker M, Zensi A, Kufleitner J, et al. A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation [J]. Int J Pharmaceut, 2011, 414: 225-232.
[24] Wang Wentan, Huang Yanbin, Zhao Shufang, et al. Human serum albumin (HSA) nanoparticles stabilized with intermolecular disulfide bonds [J]. Chem Commun, 2013, 49(22): 2234-2236
[25] Bhushan B, Gopinath P. Antioxidant nanozyme: A facile synthesis and evaluation of reactive oxygen species scavenging potential of nanoceria encapsulated albumin nanoparticles [J]. J Mater Chem B, 2015, 3(24): 4843-4852.
[26] Peralta DV, Heidari Z, Dash S, et al. Hybrid paclitaxel and gold nanorod-loaded human serum albumin nanoparticles for simultaneous chemotherapeutic and photothermal therapy on 4T1 breast cancer cells [J]. ACS Appl Mater Inter, 2015, 7(13): 7101-7111.
[27] Wang Lirong, Lin Hongyu, Ma Lingceng, et al. Albumin-based nanoparticles loaded with hydrophobic gadolinium chelates as T1-T2 dual-modal contrast agents for accurate liver tumor imaging [J]. Nanoscale, 2017, 9(13): 4516-4523.
[28] Wang Hangxiang, Wu Jiaping, Xu Li, et al. Albumin nanoparticle encapsulation of potent cytotoxic therapeutics shows sustained drug release and alleviates cancer drug toxicity [J]. Chem Commun, 2017, 53(17), 2618-2621.
[29] Liu Lisha, Bi Yunke, Zhou Muru, et al. Biomimetic Human Serum Albumin Nanoparticle for Efficiently Targeting Therapy to Metastatic Breast Cancers [J]. ACS Appl Mater Inter, 2017, 9(8):7435.
[30] Perriercornet JM, Marie P, Gervais P. Comparison of emulsification efficiency of protein-stabilized oil-in-water emulsions using jet, high pressure and colloid mill homogenization [J]. J Food Eng, 2005, 66(2): 211-217.
[31] Bilati U, Allemann E, Doelker E. Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles [J]. Eur J Pharm Biopharm. 2005, 59(3): 375-388.
[32] Zhou Jing, Zhang Xuanmiao, Li Mei, et al. Novel lipid hybrid albumin nanoparticle greatly lowered toxicity of pirarubicin [J]. Mol Pharmaceut, 2013, 10(10): 3832-3841.
[33] Yi Xiaoli, Lian Xianghong, Dong Jianxia, et al. Co-delivery of pirarubicin and paclitaxel by human serum albumin nanoparticles to enhance antitumor effect and reduce systemic toxicity in breast cancers [J]. Mol Pharmaceut, 2015, 12(11): 4085-4098.
[34] Martinez NY, Andrade PF, Durán N, et al. Development of double emulsion nanoparticles for the encapsulation of bovine serum albumin [J]. Colloids Surf B: Biointerfaces, 2017, 158: 190-196.
[35] Min SY, Byeon HJ, Lee C, et al. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer [J]. Int J Pharmaceut, 2015, 494(1): 506-515.
[36] Desai N. Nanoparticle albumin bound (nab) technology: targeting tumors through the endothelial gp60 receptor and SPARC [J]. Nanomedicine: Nanotechnology, Biology and Medicine, 2007, 3(4): 339-339.
[37] Kim B, Seo BH, Park SH, et al. Albumin nanoparticles with synergistic antitumor efficacy against metastatic lung cancers [J]. Colloids Surf B: Biointerfaces, 2017, 158: 157-166.
[38] Green MR, Manikhas GM, Orlov S, et al. Abraxane?, a novel cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer [J]. Ann Oncol, 2006, 17(8): 1263-1268.
[39] Kim TH, Jiang HH, Youn YS, et al. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity [J]. Int J Pharmaceut, 2011, 403: 285-291.
[40] Wan Xu, Zheng Xiaoyao, Pang Xiaoying, et al. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer [J]. Int J Pharmaceut, 2015, 484: 16-28.
[41] Thao LQ, Byeon HJ, Lee C, et al. Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues [J]. Int J Pharmaceut, 2016, 497: 268-276.
[42] Qi Jianing, Yao Ping, He Fen, et al. Nanoparticles with dextran/chitosan shell and BSA/chitosan core--doxorubicin loading and delivery [J]. Int J Pharmaceut, 2010, 393: 176-184.
[43] Schafroth N, Arpagaus C, Jadhav UY, et al. Nano and microparticle engineering ofwater insoluble drugs using a novel spray-drying process [J]. Colloids Surf B: Biointerfaces, 2012, 90: 8-15.
[44] Lee SH, Heng D, Ng WK, et al. Nano spray drying: A novel method for preparing protein nanoparticles for protein therapy [J]. Int J Pharmaceut, 2011, 403: 192-200.
[45] Yu Cong, Wo Fangjie, Shao Yuxiang, et al. Bovine serum albumin nanospheres synchronously encapsulating “gold selenium/gold” nanoparticles and photosensitizer for high-efficiency cancer phototherapy [J]. Appl Biochem Biotech, 2013, 169(5):1566-1578.
[46] Gong Guangming, Pan Qinqin, Wang Kaikai, et al. Curcumin-incorporated albumin nanoparticles and its tumor image [J]. Nanotechnology, 2015, 26(4): 045603.
[47] Wang Shudong, Gong Guangming, Su Hua, et al. Self-assembly of plasma protein through disulfide bond breaking and its use as a nanocarrier for lipophilic drugs [J]. Polym Chem-UK, 2014, 5(17): 4871-4874.
[48] Tang Xiaolei, Wang Guijun, Shi Runjie, et al. Enhanced tolerance and antitumor efficacy by docetaxel-loaded albumin nanoparticles [J]. Drug Deliv, 2015, 23(8): 1-11.
[49] Yuan Ahu, Wu Jinhui, Song Chenchen, et al. A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity [J]. J Pharm Sci-US, 2013, 102(5): 1626-1635.
[50] Asghar S, Salmani JMM, Hassan W, et al. A facile approach for crosslinker free nano self assembly of protein for anti-tumor drug delivery: factors' optimization, characterization and in vitro evaluation [J]. Eur J Pharm Sci, 2014, 63: 53-62.
[51] Chen Qian, Wang Xin, Wang Chao, et al. Drug-Induced Self-Assembly of Modified Albumins as Nanotheranostics for Tumor-Targeted Combination Therapy [J]. ACS Nano, 2015, 9(5): 5223-5233.
[52] Lin Tingting, Zhao Pengfei, Jiang Yifan, et al. Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy [J]. ACS Nano, 2016, 10(11): 9999-10012.
[53] Safavi MS, Shojaosadati SA, Yang HG, et al.Reducing agent-free synthesis of curcumin-loaded albumin nanoparticles by self-assembly at room temperature [J]. Int J Pharmaceut, 2017, 529: 303-309.
[54] Lin W, Coombes AGA, Davies MC, et al. Preparation of sub-400 nm human serum albumin nanospheres using a pH-coacervation method [J]. J Drug Target, 1993, 1(3): 237-243.
[55] Lin Wu, Garnett MC, Davis SS, et al. Preparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticles [J]. J Control Release, 2001, 71(1): 117-126.
[56] Wilson B, Lavanya Y, Priyadarshini SRB, et al. Albumin nanoparticles for the delivery of gabapentin: Preparation, characterization and pharmacodynamic studies [J]. Int J Pharmaceut, 2014, 473(1-2): 73-79.
[57] Gong Guangming, Xu Yan, Zhou Yuanyuan, et al. Molecular switch for the assembly of lipophilic drug incorporated plasma protein na-noparticles and in vivo image [J]. Biomacromolecules, 2012, 13(1): 23-28.
[2] Sun Tianmeng, Zhang YS, Pang Bo, et al. Engineered nanoparticles for drug delivery in cancer therapy [J]. Angew Chem Int Edit, 2014, 53(46): 12320-12364.
[3] Kinoshita R, Ishima Y, Chuang VTG, et al. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer [J]. Biomaterials, 2017, 140: 162-169.
[4] Loureiro A, Azoia NG, Gomes AC, et al. Albumin-based nanodevices as drug carriers [J]. Curr Pharm Design, 2016, 22(10): 1371-1390.
[5] Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles [J]. J Control Release, 2008, 132(3): 171-183.
[6] Hawkins MJ, Soon-shiong P, Desai N. Protein nanoparticles as drug carriers in cli-nical medicine [J]. Adv Drug Deliv Rev, 2008, 60(8): 876-885.
[7] Lin Tingting, Zhao Pengfei, Jiang Yifan, et al. Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy [J]. ACS Nano, 2016, 10(11): 9999-10012.
[8] Chen Qian, Liu Zhuang. Albumin carriers for cancer theranostics: A conventional platform with new promise [J]. Adv Mater, 2016, 28(47):10557-10566.
[9] Kudarha RR, Sawant KK. Albumin based versatile multifunctional nanocarriers for cancer therapy: Fabrication, surface modification, multimodal therapeutics and imaging approaches [J]. Mater Sci Eng C, 2017, 81:607-626.
[10] Sheng Zonghai, Hu Dehong, Zheng Mingbin, et al. Smart human serum albumin-indocyanine green nanoparticles generated by programmed assembly for dual-modal imaging-guided cancer synergistic phototherapy [J]. ACS Nano, 2014, 8(12): 12310-12322.
[11] Wong LR, Ho PC. Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: Implications for the treatment of Alzheimer′s disease [J]. J Pharm Pharmacol, 2018, 70(1): 59-69.
[12] Jeong JH, Nguyen HK, Lee JE, et al. Therapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage [J]. Int J Nanomed, 2016, 11: 3101-3109.
[13] Langiu M, Dadparvar M, Kreuter J, et al. Human serum albumin-based nanoparticle-mediated in vitro gene delivery [J]. PLoS ONE, 2014, 9(9).
[14] Adiseshaiah PP, Crist RM, Hook SS, et al. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer [J]. Nat Rev Clin Oncol, 2016, 13(12): 750-765.
[15] Sundar S, Kundu J, Kundu SC. Biopolymeric nanoparticles [J]. Sci Technol Adv Mater, 2010, 11(1): 014104.
16] Kratz F. A clinical update of using albumin as a drug vehicle — A commentary [J]. J Control Release, 2014, 190(190): 331-336.
[17] Carter DC, He X, Munson SH, et al. Three-dimensional structure of human serum albumin [J]. Science, 1989, 244(4909): 1195-1198.
[18] Zsila F. Subdomain IB is the third major drug binding region of human serum albumin: toward the three-sites model [J]. Mol Pharmaceut, 2013, 10(5): 1668-1682.
[19] Jahanban-Esfahlan A, Dastmalchi S, Davaran S. A simple improved desolvation method for the rapid preparation of albumin nanoparticles [J]. Int J Biol Macromol, 2016, 91: 703-709.
[20] Bunschoten A, Buckle T, Kuil J, et al. Targeted non-covalent self-assembled nanoparticles based on human serum albumin [J]. Biomaterials, 2012, 33(3): 867-875.
[21] Majorek KA, Porebski PJ, Dayal A, et al. Structural and immunologic characterization of bovine, horse, and rabbit serum albumins [J]. Mol Immunol, 2012, 52: 174-182.
[22] Furst W, Banerjee A. Release of glutaraldehyde from an albumin-glutaraldehyde tissue adhesive causes significant in vitro and in vivo toxicity [J]. Ann Thorac Surg, 2005, 79(5): 1522-1529.
[23] Wacker M, Zensi A, Kufleitner J, et al. A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation [J]. Int J Pharmaceut, 2011, 414: 225-232.
[24] Wang Wentan, Huang Yanbin, Zhao Shufang, et al. Human serum albumin (HSA) nanoparticles stabilized with intermolecular disulfide bonds [J]. Chem Commun, 2013, 49(22): 2234-2236
[25] Bhushan B, Gopinath P. Antioxidant nanozyme: A facile synthesis and evaluation of reactive oxygen species scavenging potential of nanoceria encapsulated albumin nanoparticles [J]. J Mater Chem B, 2015, 3(24): 4843-4852.
[26] Peralta DV, Heidari Z, Dash S, et al. Hybrid paclitaxel and gold nanorod-loaded human serum albumin nanoparticles for simultaneous chemotherapeutic and photothermal therapy on 4T1 breast cancer cells [J]. ACS Appl Mater Inter, 2015, 7(13): 7101-7111.
[27] Wang Lirong, Lin Hongyu, Ma Lingceng, et al. Albumin-based nanoparticles loaded with hydrophobic gadolinium chelates as T1-T2 dual-modal contrast agents for accurate liver tumor imaging [J]. Nanoscale, 2017, 9(13): 4516-4523.
[28] Wang Hangxiang, Wu Jiaping, Xu Li, et al. Albumin nanoparticle encapsulation of potent cytotoxic therapeutics shows sustained drug release and alleviates cancer drug toxicity [J]. Chem Commun, 2017, 53(17), 2618-2621.
[29] Liu Lisha, Bi Yunke, Zhou Muru, et al. Biomimetic Human Serum Albumin Nanoparticle for Efficiently Targeting Therapy to Metastatic Breast Cancers [J]. ACS Appl Mater Inter, 2017, 9(8):7435.
[30] Perriercornet JM, Marie P, Gervais P. Comparison of emulsification efficiency of protein-stabilized oil-in-water emulsions using jet, high pressure and colloid mill homogenization [J]. J Food Eng, 2005, 66(2): 211-217.
[31] Bilati U, Allemann E, Doelker E. Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles [J]. Eur J Pharm Biopharm. 2005, 59(3): 375-388.
[32] Zhou Jing, Zhang Xuanmiao, Li Mei, et al. Novel lipid hybrid albumin nanoparticle greatly lowered toxicity of pirarubicin [J]. Mol Pharmaceut, 2013, 10(10): 3832-3841.
[33] Yi Xiaoli, Lian Xianghong, Dong Jianxia, et al. Co-delivery of pirarubicin and paclitaxel by human serum albumin nanoparticles to enhance antitumor effect and reduce systemic toxicity in breast cancers [J]. Mol Pharmaceut, 2015, 12(11): 4085-4098.
[34] Martinez NY, Andrade PF, Durán N, et al. Development of double emulsion nanoparticles for the encapsulation of bovine serum albumin [J]. Colloids Surf B: Biointerfaces, 2017, 158: 190-196.
[35] Min SY, Byeon HJ, Lee C, et al. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer [J]. Int J Pharmaceut, 2015, 494(1): 506-515.
[36] Desai N. Nanoparticle albumin bound (nab) technology: targeting tumors through the endothelial gp60 receptor and SPARC [J]. Nanomedicine: Nanotechnology, Biology and Medicine, 2007, 3(4): 339-339.
[37] Kim B, Seo BH, Park SH, et al. Albumin nanoparticles with synergistic antitumor efficacy against metastatic lung cancers [J]. Colloids Surf B: Biointerfaces, 2017, 158: 157-166.
[38] Green MR, Manikhas GM, Orlov S, et al. Abraxane?, a novel cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer [J]. Ann Oncol, 2006, 17(8): 1263-1268.
[39] Kim TH, Jiang HH, Youn YS, et al. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity [J]. Int J Pharmaceut, 2011, 403: 285-291.
[40] Wan Xu, Zheng Xiaoyao, Pang Xiaoying, et al. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer [J]. Int J Pharmaceut, 2015, 484: 16-28.
[41] Thao LQ, Byeon HJ, Lee C, et al. Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues [J]. Int J Pharmaceut, 2016, 497: 268-276.
[42] Qi Jianing, Yao Ping, He Fen, et al. Nanoparticles with dextran/chitosan shell and BSA/chitosan core--doxorubicin loading and delivery [J]. Int J Pharmaceut, 2010, 393: 176-184.
[43] Schafroth N, Arpagaus C, Jadhav UY, et al. Nano and microparticle engineering ofwater insoluble drugs using a novel spray-drying process [J]. Colloids Surf B: Biointerfaces, 2012, 90: 8-15.
[44] Lee SH, Heng D, Ng WK, et al. Nano spray drying: A novel method for preparing protein nanoparticles for protein therapy [J]. Int J Pharmaceut, 2011, 403: 192-200.
[45] Yu Cong, Wo Fangjie, Shao Yuxiang, et al. Bovine serum albumin nanospheres synchronously encapsulating “gold selenium/gold” nanoparticles and photosensitizer for high-efficiency cancer phototherapy [J]. Appl Biochem Biotech, 2013, 169(5):1566-1578.
[46] Gong Guangming, Pan Qinqin, Wang Kaikai, et al. Curcumin-incorporated albumin nanoparticles and its tumor image [J]. Nanotechnology, 2015, 26(4): 045603.
[47] Wang Shudong, Gong Guangming, Su Hua, et al. Self-assembly of plasma protein through disulfide bond breaking and its use as a nanocarrier for lipophilic drugs [J]. Polym Chem-UK, 2014, 5(17): 4871-4874.
[48] Tang Xiaolei, Wang Guijun, Shi Runjie, et al. Enhanced tolerance and antitumor efficacy by docetaxel-loaded albumin nanoparticles [J]. Drug Deliv, 2015, 23(8): 1-11.
[49] Yuan Ahu, Wu Jinhui, Song Chenchen, et al. A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity [J]. J Pharm Sci-US, 2013, 102(5): 1626-1635.
[50] Asghar S, Salmani JMM, Hassan W, et al. A facile approach for crosslinker free nano self assembly of protein for anti-tumor drug delivery: factors' optimization, characterization and in vitro evaluation [J]. Eur J Pharm Sci, 2014, 63: 53-62.
[51] Chen Qian, Wang Xin, Wang Chao, et al. Drug-Induced Self-Assembly of Modified Albumins as Nanotheranostics for Tumor-Targeted Combination Therapy [J]. ACS Nano, 2015, 9(5): 5223-5233.
[52] Lin Tingting, Zhao Pengfei, Jiang Yifan, et al. Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy [J]. ACS Nano, 2016, 10(11): 9999-10012.
[53] Safavi MS, Shojaosadati SA, Yang HG, et al.Reducing agent-free synthesis of curcumin-loaded albumin nanoparticles by self-assembly at room temperature [J]. Int J Pharmaceut, 2017, 529: 303-309.
[54] Lin W, Coombes AGA, Davies MC, et al. Preparation of sub-400 nm human serum albumin nanospheres using a pH-coacervation method [J]. J Drug Target, 1993, 1(3): 237-243.
[55] Lin Wu, Garnett MC, Davis SS, et al. Preparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticles [J]. J Control Release, 2001, 71(1): 117-126.
[56] Wilson B, Lavanya Y, Priyadarshini SRB, et al. Albumin nanoparticles for the delivery of gabapentin: Preparation, characterization and pharmacodynamic studies [J]. Int J Pharmaceut, 2014, 473(1-2): 73-79.
[57] Gong Guangming, Xu Yan, Zhou Yuanyuan, et al. Molecular switch for the assembly of lipophilic drug incorporated plasma protein na-noparticles and in vivo image [J]. Biomacromolecules, 2012, 13(1): 23-28.